Rutamarin

CAS: 13164-05-1

Ref. 3D-NAA16405

Informação sobre produto

• Nome: Rutamarin
• Sinónimos: (+)-Rutamarin, (2S)-2-[1-(Acetyloxy)-1-methylethyl]-6-(1,1-dimethyl-2-propen-1-yl)-2,3-dihydro-7H-furo[3,2-g][1]benzopyran-7-one, 7H-Furo[3,2-g][1]benzopyran-7-one, 2-[1-(acetyloxy)-1-methylethyl]-6-(1,1-dimethyl-2-propenyl)-2,3-dihydro-, (2S)-, 7H-Furo[3,2-g][1]benzopyran-7-one, 6-(1,1-dimethylallyl)-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-, acetate, 7H-Furo[3,2-g][1]benzopyran-7-one, 6-(1,1-dimethylallyl)-2,3-dihydro-2-(1-hydroxy-1-methylethyl)-,acetate (8CI), 7H-Furo[3,2-g][1]benzopyran-7-one,2-[1-(acetyloxy)-1-methylethyl]-6-(1,1-dimethyl-2-propenyl)-2,3-dihydro-, (2S)-(9CI), 7H-Furo[3,2-g][1]benzopyran-7-one,2-[1-(acetyloxy)-1-methylethyl]-6-(1,1-dimethyl-2-propenyl)-2,3-dihydro-, (S)-, Chalepin acetate, NSC 263654, S-(+)-Chalepin acetate

Descrição

Rutamarin is a low molecular weight inhibitor with a molecular weight of 567. It binds to the ATP binding site of the mitochondrial membrane, thereby inhibiting its function. Rutamarin inhibits the production of inflammatory mediators in vitro and in vivo by inhibiting cyclooxygenase-2 (COX-2) and the COX-2-dependent synthesis of prostaglandins. Rutamarin also causes a reduction in colorectal adenocarcinoma cells, as well as metabolic profiles that are associated with carcinomas. This drug also affects fatty acid metabolism, which may be due to its inhibition of peroxisome proliferator activated receptor (PPAR).

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 356.4 g/mol
• Fórmula: C₂₁H₂₄O₅
• Pureza: Min. 95%
• Cor/forma: Powder